• Vaccine Name: L. major DNA Vaccine encoding LACKp24, TSA, LmSTI1 and CPa
• Target Pathogen: Leishmania major
• Target Disease: Cutaneous leishmaniasis
• Vaccine Ontology ID: VO_0004171
• Type: DNA vaccine
• Status: Research
• TSA gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Cpa gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• LmSTI1 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• LACK gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005058
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: For mice immunization, a single dose of 50 μg of Qiagen purified plasmid of each candidate DNA vaccine was administered intramusculary in 100 μl of PBS, 50 μl in each anterior tibialis muscle. Sham vaccination consisted of a single injection of 50 μg or 200 μg of Qiagen purified pCMV3ISS, the plasmid backbone, in the same conditions as immunized mice. A further control group of mice received no treatment at all (PBS). A group of mice was vaccinated with a cocktail of all 4 antigen carrying plasmids (pCMV3ISS-LACKp24, pCMV3ISS-TSA, pCMV3ISS-LmSTI1 and pCMV3ISS-CPa) (Ahmed et al., 2009).
• Challenge Protocol: The appropriate number of promastigotes was inoculated subcutaneously in the right hind footpad of female BALB/c mice in 50 μl of PBS. The challenge of mice was carried out 2 weeks after the immunization (Ahmed et al., 2009).
• Efficacy: A substantial increase of protection was achieved when the cocktail is composed of all of the four antigens; however, no full protection was achieved when mice were challenged with a high dose of parasite in their hind footpad. The full protection was only achieved after a challenge with a low parasitic dose in the dermis of the ear (Ahmed et al., 2009).